Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00651027 | Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554 | PHASE1 | COMPLETED | 24 | — | — | Feb 1, 2008 | Sep 1, 2008 | Jan 3, 2014 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | 200 mg |
| Name | Type | Description |
|---|---|---|
| PF-868554 | DRUG | 200 mg, Child-Pugh Class A |
Inclusion Criteria: * Male or females subjects of non-childbearing potential between the ages of 18 and 62 years of age, inclusive; * Body Mass Index (BMI) of approximately 18 to 35 kg/m2; and a total body weigh \>50 kg (110 lbs); Exclusion Criteria: * Subjects with Class C classification (Severe...